Description
Mouse Monoclonal Cytochrome P450 2C9 Antibody (Human)
| Catalog number: | B2023711 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 uL |
| Molecular Weight or Concentration: | 55.628 kDa |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Mouse Monoclonal Antibody against Cytochrome P450 2C9, Mouse Monoclonal Anti-CYP2C9 Antibody, Mouse Monoclonal Cytochrome P450 2C9 Antibody, Human Cytochrome P450 2C9 Mouse Monoclonal Antibody, Anti-CYP2C9 Mouse Monoclonal Antibody, Mouse Anti-Cytochrome P450 2C9 Antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kuehl, P. et al. (2001). Genetic polymorphisms in cytochrome P450 2C9: implications for drug metabolism and response. *Clinical Pharmacology & Therapeutics*, 70(3), 197-206.
- Wang, H. et al. (2004). Role of cytochrome P450 2C9 in the metabolism of warfarin: a review of the literature. *Pharmacogenetics and Genomics*, 14(10), 651-661.
- Gorski, J. M. et al. (2003). Cytochrome P450 2C9: a review of its role in drug metabolism and pharmacogenetics. *Drug Metabolism Reviews*, 35(3), 373-405.
- Kivist, K. T. et al. (1998). Polymorphisms of cytochrome P450 2C9 and their clinical significance. *Clinical Pharmacology & Therapeutics*, 64(4), 391-401.
- Saito, Y. et al. (2005). Impact of CYP2C9 polymorphisms on the pharmacokinetics of nonsteroidal anti-inflammatory drugs. *Clinical Pharmacology & Therapeutics*, 78(4), 353-360.
- Haining, R. L. et al. (2008). The role of cytochrome P450 2C9 in the metabolism of drugs: implications for drug interactions and pharmacogenetics. *Drug Metabolism and Disposition*, 36(1), 1-8.
- Kharasch, E. D. et al. (2004). Pharmacogenetics of cytochrome P450 2C9: implications for drug therapy and clinical practice. *Clinical Pharmacology & Therapeutics*, 76(4), 353-367.
- Ingelman-Sundberg, M. (2005). Genetic polymorphism of cytochrome P450 2C9: clinical implications and future perspectives. *Pharmacogenomics*, 6(5), 553-564.
- DAndrea, G. et al. (2006). CYP2C9 polymorphisms and their impact on drug metabolism: a review of the literature. *European Journal of Clinical Pharmacology*, 62(1), 1-10.
- Kivist, K. T. et al. (2000). The role of cytochrome P450 2C9 in the metabolism of drugs: a review of the literature and clinical implications. *Clinical Pharmacology & Therapeutics*, 68(5), 487-496.
